| First Author | Yang X | Year | 2018 |
| Journal | Biochem Biophys Res Commun | Volume | 501 |
| Issue | 1 | Pages | 41-47 |
| PubMed ID | 29680659 | Mgi Jnum | J:270298 |
| Mgi Id | MGI:6276674 | Doi | 10.1016/j.bbrc.2018.04.126 |
| Citation | Yang X, et al. (2018) Tracing the dynamic expression of the Nfkappab2 gene during inflammatory processes by in vivo bioluminescence imaging in transgenic mice. Biochem Biophys Res Commun 501(1):41-47 |
| abstractText | Nfkappab2(p52/p100) plays essential roles in many chronic inflammatory diseases. Tracing the dynamic expression of Nfkappab2 during different biological processes in vivo can provide valuable clues to understand the biological functions of this gene and develop anti-inflammatory drugs. In this study, B6-Tg(Nfkappab2-luc)(Mlit) transgenic mouse line, a mouse model in which the expression of firefly luciferase gene is under the control of a 14.6-kb mouse Nfkappab2 promoter, was generated to monitor the expression of p52/p100 in vivo. Bioluminescence imaging was used for tracking the luciferase signal in living mice in a variety of inflammatory processes, including LPS-induced sepsis and inflammatory bowel disease (IBD). The data of in vivo bioluminescence imaging in this mouse model showed that luciferase activity coincided with the endogenous p52/p100 expression. Moreover, dexamethasone or aspirin, two routine anti-inflammatory drugs, could decrease the high-level expression of luciferase induced by LPS. Overall, our results suggest that the B6-Tg(Nfkappab2-luc)(Mlit) mice represent a valuable reporter mouse model not only to monitor the expression of p52/p100 in physiological or pathological processes but also to evaluate the effects of various anti-inflammatory drug treatments in vivo. |
